Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advertisement
Katy MarshallSUO 2023 | November 30, 2023
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Read More
Zachary BessetteSUO 2023 | November 30, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Zachary BessetteSUO 2023 | November 22, 2023
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Emily Menendez2023 IKCS: North America | November 13, 2023
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Katy Marshall2023 IKCS: North America | November 10, 2023
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Emily MenendezLocalized Renal Cell Carcinoma | November 8, 2023
The anti-PD-1 therapy met the trial’s key secondary endpoint of OS for patients with RCC following nephrectomy.
Emily MenendezLocalized Renal Cell Carcinoma | November 3, 2023
Certain risk factors can result in pathological upstaging in patients treated with nephrectomy for nonmetastatic RCC.
Zachary BessetteASTRO 2023 | October 3, 2023
New data compares renal function outcomes of SABR in patients with solitary versus bilateral kidneys.
Zachary BessetteASTRO 2023 | October 2, 2023
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation.
Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Akhil Abraham Saji, MDLocalized | November 29, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Emily MenendezLocalized Renal Cell Carcinoma | August 29, 2023
While nephrectomy is a common treatment for kidney cancer, it can result in loss of kidney function or kidney failure.
Emily MenendezLocalized Renal Cell Carcinoma | August 18, 2023
The EVEREST trial analyzed the effectiveness of everolimus in patients with RCC who have undergone full surgical resection.
Jérémie Calais, MD, MScSNMMI 2023 | July 28, 2023
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Leah LawrenceLocalized Renal Cell Carcinoma | July 7, 2023
Several experts discuss the evolution of nephrectomy, how it is used today, which patients are best suited for it, and more.
Emily MenendezLocalized Renal Cell Carcinoma | June 26, 2023
To identify positive surgical margins, researchers used DESI-MSI to to distinguish normal tissue from RCC tissue samples.
Zachary BessetteASCO 2023 | May 30, 2023
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Emily MenendezLocalized Renal Cell Carcinoma | May 11, 2023
Partial nephrectomy has been gaining traction as an effective treatment for RCC due to its safety and efficacy.
Advertisement
Advertisement
Advertisement